E. James Song, MD, FAAD
Co-Chief Medical Officer and Director of Clinical Research, Frontier Dermatology,
Mill Creek, WA
Disclosure
Advisory Board: AbbVie, Alumis, Alphyn, Amgen, Apogee, Arcutis, BMS, Boehringer-Ingelheim, Dermavant/Organon, DermBiont, Galderma, Incyte, Johnson &, LEO, Novartis, Ortho-dermatologics, Pfizer, Sanofi & Regeneron, SUN
Grant/Research Support: AbbVie, Alumis, Amgen, Apogee, Arcutis, BMS, DermBiont, Incyte, Johnson & Johnson, LEO, MoonLake, Pfizer, Veraderimcs, TARGET, CorEvitas
Consultant: AbbVie, Alumis, Alphyn, Amgen, Apogee, Arcutis, BMS, Boehringer-Ingelheim, Dermavant/Organon, DermBiont, Galderma, Incyte, Johnson &, LEO, Novartis, Ortho-dermatologics, Pfizer,Sanofi & Regeneron, SUN
Speakers’ Bureau or Honoraria: AbbVie, Amgen, Arcutis, BMS,Dermavant/Organon, Galderma, Incyte, Johnson & Johnson, LEO Ortho-dermatologics, Pfizer, Phothera, UCB, SUN